Fact CheckerSign in

NCT07563920Not yet recruiting

TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission

A Single-Center, Prospective, Single-Arm Clinical Study Evaluating the Efficacy and Safety of Thiotepa, Busulfan, and Fludarabine (TBF) Conditioning Regimen in Haploidentical Peripheral Blood Stem Cell Transplantation for Elderly Acute Myeloid Leukemia Patients in First Complete Remission

Source: ClinicalTrials.gov · Last updated 4 May 2026

Brief summary (registry, in English)

Acute myeloid leukemia (AML) is a serious blood cancer that mainly affects older adults. For patients who achieve their first complete remission (CR1), allogeneic hematopoietic stem cell transplantation (HSCT) may provide a chance for long-term survival. However, relapse after transplantation remains a major challenge. This study aims to evaluate the effectiveness and safety of a conditioning regimen that combines thiotepa, busulfan, and fludarabine (TBF) before haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) in elderly patients with AML in first complete remission. Eligible patients will receive the TBF conditioning regimen followed by stem cell transplantation from a partially matched donor. Participants will be followed to assess relapse-free survival, overall survival, transplant-related complications, and infections. The results of this study may help improve treatment strategies and outcomes for elderly AML patients undergoing transplantation.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
93 (estimated)
First submitted
26 Apr 2026
Start date
Jun 2026
Primary completion date
Jun 2029
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT number
NCT07563920

What you commit to

  • Study type: Interventional
  • Planned participants: 93
  • From Jun 2026 to the primary completion date, Jun 2029
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Secondary AML (including AML evolving from myelodysplastic syndrome or therapy-related AML)
  • Active, uncontrolled infection
  • Severe uncontrolled systemic disease (e.g., unstable cardiovascular disease, recent stroke, or severe organ dysfunction)
  • HIV infection
  • Active hepatitis B or C requiring antiviral treatment
  • Known hypersensitivity to study drugs

Other

  • Pregnant or breastfeeding women

Who the study is looking for

  • Age 55 to 75 years
  • Diagnosed with acute myeloid leukemia (AML) based on morphology, immunophenotyping, cytogenetics, or molecular testing
  • First complete remission (CR1) or complete remission with incomplete hematologic recovery (CRi)
  • Eligible for haploidentical hematopoietic stem cell transplantation
  • Availability of a suitable haploidentical donor
  • ECOG performance status 0-2
  • Adequate organ function:
    • Left ventricular ejection fraction ≥50%
    • Oxygen saturation \>92% on room air
    • Serum creatinine ≤1.5 × upper limit of normal (ULN)
    • Total bilirubin ≤1.5 × ULN
    • AST and ALT ≤2.0 × ULN
    • DLCO ≥40% and FEV1 ≥50%
  • Ability to understand and sign informed consent

Age in the registry: 55 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.